LeanTaaS

LeanTaaS was founded by Mohan Giridharadas, who holds an MBA from Stanford, an MS in computer science from Georgia Tech, and a B.Tech from IIT Bombay. He spent 18 years at McKinsey & Company as a partner and later led global operational excellence at Emerson, a Fortune 500 industrial firm. His father, B.V. Giridharadas, founded a major venture capital firm in India, and his brother is the author Anand Giridharadas.

LeanTaaS licenses AI-powered SaaS products under the 'iQueue' brand to hospitals and health systems. The platform applies machine learning and queueing theory to optimize scheduling and utilization of high-cost assets: operating rooms, infusion chairs, and inpatient beds. It does not sell consulting services or hardware — the revenue model is annual software subscriptions.

Insight Partners, a global software investor with over $80B in assets under management, led the firm's growth rounds and is the most prominent backer. Goldman Sachs Growth Equity is also a significant investor. Other backers have included Sedgwick and earlier-stage venture firms, though Insight is generally considered the controlling external shareholder.

No. LeanTaaS is a venture-backed healthcare AI software company. It appears in Altss research because institutional investors, including family offices, have exposure to it directly via venture capital commitments to Insight Partners and Goldman Sachs, or through co-investment rights alongside those sponsors.

According to public statements made by the firm, its iQueue platform is used to manage scheduling and capacity for operating rooms, infusion chairs, and inpatient beds at hundreds of hospitals and health systems, encompassing roughly one-third of all US acute-care beds. It counts several of the largest and most prestigious cancer centers and academic medical centers as clients.